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Objective: To compare the diagnostic value of striatal 123I-2b-carbomethoxy-3b-(4-iodophenyl)-N-(3-fluoropropyl)
nortropane (123I-FP-CIT) single photon emission computed tomography (SPECT) and 123I-metaiodobenzylguanidine
(123I-MIBG) myocardial scintigraphy in differentiating dementia with Lewy bodies (DLB) from other dementia types.
Methods: This prospective longitudinal study included 30 patients with a clinical diagnosis of DLB and 29 patients
with non-DLB dementia (Alzheimer disease, n516; behavioral variant frontotemporal dementia, n5 13). All patients
underwent 123I-FP-CIT SPECT and 123I-MIBG myocardial scintigraphy within a few weeks of clinical diagnosis. All
diagnoses at each center were agreed upon by the local clinician and an independent expert, both unaware of
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imaging data, and re-evaluated after 12 months. Each image was visually classified as either normal or abnormal by
3 independent nuclear physicians blinded to patients’ clinical data.
Results: Overall, sensitivity and specificity to DLB were respectively 93% and 100% for 123I-MIBG myocardial scintig-
raphy, and 90% and 76% for 123I-FP-CIT SPECT. Lower specificity of striatal compared to myocardial imaging was
due to decreased 123I-FP-CIT uptake in 7 non-DLB subjects (3 with concomitant parkinsonism) who had normal 123I-
MIBG myocardial uptake. Notably, in our non-DLB group, myocardial imaging gave no false-positive readings even
in those subjects (n5 7) with concurrent medical illnesses (diabetes and/or heart disease) supposed to potentially
interfere with 123I-MIBG uptake.
Interpretation: 123I-FP-CIT SPECT and 123I-MIBG myocardial scintigraphy have similar sensitivity for detecting DLB,
but the latter appears to be more specific for excluding non-DLB dementias, especially when parkinsonism is the
only “core feature” exhibited by the patient. Our data also indicate that the potential confounding effects of diabe-
tes and heart disease on 123I-MIBG myocardial scintigraphy results might have been overestimated.
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Once thought to be uncommon, dementia withLewy bodies (DLB) is currently regarded as the
most common form of dementia in the elderly after Alz-
heimer disease (AD).1 Besides cognitive impairment, the
DLB Consortium originally described 3 core clinical fea-
tures of DLB (fluctuations, visual hallucinations [VHs],
and spontaneous parkinsonism),2 but because these fea-
tures may not invariably appear during the disease
course3 or may overlap to some extent with other
dementias,4,5 clinical diagnostic accuracy in clinicopatho-
logic studies has, with one notable exception,6 been rela-
tively poor.7–11 Although the subsequent addition of
rapid eye movement sleep behavior disorder (RBD) in
the diagnostic algorithm12 has improved DLB identifica-
tion,13 its differentiation from other dementias remains a
challenge even for experienced clinicians.
In light of the limitations on the level of accuracy
that can be achieved by making a diagnosis of DLB
only on clinical grounds, great emphasis has recently
been placed on imaging methods targeting some of its
typical biological alterations, including degeneration of
the nigrostriatal dopaminergic system and of postgangli-
onic sympathetic cardiac innervation. Reflecting these
pathologic changes, abnormal findings (low uptake) on
either dopamine transporter (DAT) single photon emis-
sion computed tomography (SPECT), using 123I-2b-
carbomethoxy-3b-(4-iodophenyl)-N-(3-fluoropropyl)
nortropane (123I-FP-CIT),14–16 or myocardial scintigra-
phy, using 123I-metaiodobenzylguanidine (123I-
MIBG),17 have consistently been reported to be useful
markers to support the diagnosis of DLB.18,19 However,
although the diagnostic value of both imaging methods
has been acknowledged in the latest formulation of
DLB consensus criteria,12 only abnormalities on DAT
imaging have been considered to have enough specific-
ity to be ranked among DLB “suggestive features.”
DAT SPECT abnormalities have been shown to be
highly specific in differentiating DLB from AD because,
in the latter condition, the nigrostriatal dopaminergic
system is usually intact and, consequently, striatal tracer
binding is normal.14–16 Nonetheless, specificity of DAT
imaging is expected to decrease when the differential
diagnosis is not between DLB and AD, but between
DLB and disorders, such as vascular or frontotemporal
dementias, that may also result in loss of nigrostriatal
integrity.20,21 It is also worth highlighting that an
abnormal DAT SPECT would not be useful for sup-
porting a hypothetical diagnosis of DLB if parkinson-
ism is the only “core” feature exhibited by the patient
because, in this case, a decrease in striatal tracer binding
is expectable (circularity).
Unlike DAT SPECT, 123I-MIBG scintigraphy
results are independent of the presence of parkinsonism17
and integrity of postganglionic sympathetic cardiac inner-
vation is unaffected by dementias other than DLB.20,22
Conversely, compared to DAT SPECT, 123I-MIBG scin-
tigraphy may have some disadvantages, such as the find-
ing that several common illnesses in the elderly
(including heart infarct, heart failure, dilated cardiomy-
opathy, and autonomic diabetic neuropathy), if severe
enough, can interfere with 123I-MIBG uptake.23,24 Fur-
thermore, although several drugs may reduce the uptake
of both tracers,25,26 and are thus recommended to be
temporarily withdrawn before the procedures, the list of
medications potentially interfering with 123I-MIBG
uptake includes agents of more widespread use (eg, calci-
um channel blockers, labetalol).
Until now, several studies have evaluated the role of
either 123I-FP-CIT SPECT14–16 or 123I-MIBG scintigra-
phy19 in supporting DLB identification, but only 2
cross-sectional studies have compared the diagnostic value
of the two methods in concurrent samples.27,28 To our
knowledge, this is the first prospective longitudinal study
in the field. Our primary aim was to compare sensitivity
and specificity of 123I-FP-CIT SPECT and 123I-MIBG
scintigraphy in distinguishing DLB from other demen-
tias. Our secondary aim was to determine positive and
negative predictive values, as well as inter-reader agree-
ment for visual assessment of each of the two imaging
methods.
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Patients and Methods
Subjects
This study included a total of 65 subjects who were referred
between July 1 and December 31, 2012 to 5 Italian centers (1
outpatient department specifically focused on DLB and related
disorders, 2 memory clinics, and 2 centers with special expertise
in early identification of atypical dementias). To be included in
the present study, subjects had to fulfill at least 1 of the follow-
ing: original consensus criteria for DLB,2 National Institute on
Aging–Alzheimer’s Association recommendations for diagnosis
of AD,29 revised diagnostic criteria for behavioral variant fron-
totemporal dementia (bvFTD),30 or National Institute of Neu-
rological Disorders and Stroke and International Association for
Research and Education in Neurosciences criteria for vascular
dementia.31 The diagnosis of DLB was based on more restric-
tive criteria than those recently recommended by the DLB
Consortium.12 A diagnosis of probable DLB was given to
patients with at least 2 of the 3 core features (fluctuations,
VHs, and parkinsonism), but not to those with only 1 core and
1 suggestive feature. Original, instead of revised, consensus cri-
teria for DLB were chosen because of the centers’ difficulties in
accessing a polysomnographic recording for RBD confirmation
and the need of excluding 123I-FP-CIT SPECT from the diag-
nostic process, to avoid the circularity of defining our DLB
group based on the construct of interest. To be considered for
the present analysis, subjects also had to be at their first clinical
examination at the recruiting centers and, to ensure an adequate
capacity to comply with the study requirements, had to have a
Mini Mental State Examination (MMSE)32 score of at least 14,
a reliable caregiver for the whole study duration, and no dis-
ability (blindness, deafness, severe language difficulty) potential-
ly hindering the collection of reliable clinical and
neuropsychological data. Another important requirement for
subjects’ inclusion was their consent to temporarily withdraw
any of the drugs known to potentially interfere with the uptake
of either of the tracers. Unlike earlier investigations, this study
did not exclude subjects with common illnesses in the elderly
(including ischemic, hypertensive, dilated cardiomyopathy, and
diabetes) that might reduce 123I-MIBG uptake, because we felt
it important to estimate the rate of possible false-positive results
(due to the concomitance of these medical conditions) in an
unselected sample that could more faithfully reflect the “real-
life” clinical context.
Clinical Procedures
Before being enrolled in the study, which was approved by the
local ethical committees and carried out according to the Decla-
ration of Helsinki and subsequent revisions (Declaration of
Helsinki, 1997), all subjects signed written informed consent.
Once recruited into the study, all patients underwent detailed
clinical, neuropsychological, and neurological examinations.
Global tests of cognitive and functional status included the
MMSE,32 the Clinical Dementia Rating (CDR),33 the Lawton
Instrumental Activities of Daily Living Scale,34 and the Activi-
ties of Daily Living Scale.35 Presence and severity of
extrapyramidal signs were rated using the Unified Parkinson
Disease Rating Scale–III.36 Presence and severity of cognitive
fluctuations were evaluated using the Clinical Assessment of
Fluctuations37 and the Mayo Fluctuation Scale.38 Sleep distur-
bances, neuropsychiatric symptoms, and depression were respec-
tively assessed by the Epworth Sleepiness Scale,39 the
Neuropsychiatric Inventory,40 and the Cornell Depression
Scale.41 Presence and characteristics of VHs were also evaluated
using the North-East Visual Hallucinations Interview.42 The
physical impairment due to comorbid chronic medical illnesses
was assessed using the Cumulative Illness Rating Scale
(CIRS),43 which provides for 14 relatively independent areas
grouped under body systems. Ratings are made on a 5-point
“degree of severity” scale, ranging from “none” to “extremely
severe.” Two indices were derived from this scale: (1) the severi-
ty index, resulting from the mean score of the first 13 catego-
ries (thereby, not taking into account the score attributed to the
“psychiatric” category); and (2) the comorbidity index, resulting
from the number of categories with a score of at least 3 (equiv-
alent to moderate impairment).
In addition to tests of global cognitive status (MMSE
and CDR), each subject underwent a comprehensive neuropsy-
chological evaluation, including the Italian version of the
CERAD (Consortium to Establish a Registry for Alzheimer’s
Disease) neuropsychological battery,44,45 the Digit Cancellation
Test, and the Letter Verbal Fluency Test.46 This battery is com-
posed of measures from each of the cognitive domains that are
most often compromised in all types of dementia: verbal and
nonverbal long-term memory (Word List Memory, Word List
Recall, Word List Recognition, Recall of Constructional Praxis),
language (Boston Naming Test, Letter and Semantic Verbal Flu-
ency), constructional and visuospatial abilities (Constructional
Praxis, Clock Drawing Test), and attention and executive func-
tions (Digit Cancellation Test and Clock Drawing Test).
According to the local clinical practice at each center, the
diagnostic workup could also comprise supplementary exams,
including magnetic resonance examination, 18fluorodeoxyglu-
cose positron emission tomography, and lumbar puncture for
cerebrospinal fluid analysis.
All clinical diagnoses at each center were agreed upon by
2 assessors, the local clinician and an independent expert (P.T.),
and re-evaluated at a 12-month follow-up visit. The assessors
did not at any time during the study have access to striatal and
myocardial images.
Imaging Procedures
All patients underwent striatal 123I-FP-CIT SPECT and 123I-
MIBG myocardial scintigraphy within a few weeks of clinical
diagnosis. Two nuclear medicine services took part in the study.
Both had well-established expertise in 123I-FP-CIT SPECT and
123I-MIBG myocardial scintigraphy, and were equipped with
the same gamma cameras with identical collimators and spatial
resolution. Images were acquired and reconstructed according
to standardized protocols.25,26 Patients were given 400mg of
sodium perchlorate for thyroid blockade before the injection of
each tracer.
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123I-FP-CIT SPECT. Drugs known to interfere with uptake of
123I-FP-CIT25 were temporarily withdrawn before undergoing
SPECT imaging. SPECT acquisition was performed 3 to 4
hours after a single intravenous administration of tracer dose
ranging from 111 to 185MBq. Striatal images were visually
assessed by 3 independent readers (nuclear physicians with
expertise in 123I-FP-CIT SPECT [F.N., U.P.G., D.C.]) who
were blinded to all patients’ clinical data, except for age. Only a
dichotomous classification of normal versus abnormal images
was used for visual rating (Fig 1). Images showing evidence of
reduced uptake in the putamen and/or in the caudate on the
right and/or the left side were classified as abnormal. Apart
from visual analysis, which was our main outcome measure,
volume of interest (VOI)-based semiquantification of 123I-FP-
CIT striatal binding was also performed. Reconstructed images
were analyzed using BasGan V2 software,47 which determines
the uptake computation of basal ganglia after drawing automat-
ically a 3-dimensional VOI over caudate and putamen in each
hemisphere, and locating occipital VOI for background evalua-
tion. Putamen and caudate nucleus uptake was subtracted by
background uptake as follows ([caudate nucleus or putamen
uptake 2 background uptake]/background uptake), and com-
pared to a reference database of 96 healthy subjects for deter-
mining the age-adjusted values for each basal nucleus. A scan
was considered abnormal when the normalized uptake value of
at least 1 of the 4 nuclei (putamen on the right or the left side;
caudate on the right or the left side) was more than 2 standard
deviations below the mean of controls.
123I-MIBG MYOCARDIAL SCINTIGRAPHY. Drugs known to
interfere with uptake of 123I-MIBG26 were temporarily with-
drawn before undergoing myocardial imaging. After intravenous
administration of 150 to 200MBq of 123I-MIBG, planar images
of the thorax in anterior view were obtained performing static
acquisition at 15 minutes (early image) and at 4 hours (delayed
image). The total acquisition time was 10 and 15 minutes for
the early and delayed images, respectively. Myocardial images
were visually assessed by 3 independent readers (nuclear
physicians with expertise in 123I-MIBG myocardial scintigraphy
[M.L.C., D.V., A.P.]) who were blinded to all patients’ clinical
data, except for age. Only a dichotomous classification of nor-
mal versus abnormal images was used for visual rating (Fig 2).
Images showing decreased 123I-MIBG uptake in the heart were
classified as abnormal. Apart from visual analysis, which was
our main outcome measure, region of interest (ROI)-based
semiquantification of MIBG myocardial binding was also per-
formed. ROIs over the left ventricular cavity of the heart and
the upper mediastinum were manually drawn on all delayed
images by a single tracer (S.C.), blind to diagnoses and the aim
of the study. The heart to mediastinum (H/M) ratio was then
calculated by dividing the count density of the left ventricular
ROI by that of the mediastinal ROI, in keeping with the stan-
dard method previously described.17 According to the local
database of either of the nuclear medicine services, an H/M
ratio< 1.6 was considered abnormal. This ratio is quite similar
to that reported by Yoshita et al.17 Only the delayed H/M
ratios were used for analysis, because the delayed scans reflect
the active neuronal uptake of 123I-MIBG.48
Statistical Analysis
Data were analyzed using the Statistical Package for Social Sci-
ences (v22.0; Armonk, NY: IBM). Group (DLB vs non-DLB)
comparisons with regard to sociodemographic, clinical, and
neuropsychological features were performed using Student t test
for continuous variables and Pearson chi-square test for dichot-
omous variables. The significance level was set at p5 0.05. Our
primary analysis was a comparison of the results of visual assess-
ment (normal or abnormal scan) for each of the two methods
between DLB and non-DLB patients. As a secondary analysis,
we also made a comparison of semiquantitative results between
the two groups. For both visual and semiquantitative analyses,
we determined sensitivity (percentage of times the tracer uptake
was decreased in patients with a final clinical diagnosis of
DLB), specificity (percentage of times the tracer uptake was
normal in patients with a final clinical diagnosis of non-DLB
FIGURE 1: (A) Normal and (B) abnormal 123I-2b-carbomethoxy-3b-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon
emission computed tomography images. [Color figure can be viewed in the online issue, which is available at
www.annalsofneurology.org.]
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dementia), positive predictive value (PPV; the percentage of
times that the clinical diagnosis was probable DLB given that
the tracer uptake was decreased), and negative predictive value
(NPV; the percentage of times that the clinical diagnosis was
non-DLB given that the tracer uptake was normal). The PPV
and NPV can be calculated for any prevalence as follows:
PPV5 sensitivity3 prevalence/sensitivity3 prevalence1 (1 2
specificity)3 (1 2 prevalence); NPV5 specificity3 (1 2 prev-
alence)/(1 2 sensitivity)3 prevalence1 specificity3 (1 2 prev-
alence). Ninety-five percent confidence intervals (CIs) for these
estimates were calculated with an exact binomial procedure.
Sensitivities and specificities of the two imaging techniques
were then compared using the exact McNemar test for both
visual (overall ratings) and semiquantitative findings.
Sample size calculation was determined assuming that (1)
the proportion of DLB patients was approximately 0.5 (owing
to intentional oversampling of patients with this disease); and
(2) sensitivity and specificity rates of both 123I-FP-CIT SPECT
and 123I-MIBG myocardial scintigraphy in identification of
DLB and non-DLB cases were in the range of 80 to
90%,15,16,22 choosing a 95% CI of6 15%.49 Based on these
estimates, the total number of patients required was 56. A fur-
ther 10% was planned to be recruited to allow for dropouts
and unreadable images.
Inter-reader agreement for visual assessment (normal vs
abnormal scan) of each of the two methods was evaluated with
Cohen kappa statistic for each pair of independent image readers.
Results
Of the 65 subjects enrolled, 1 with a clinical diagnosis of
probable AD did not meet inclusion criteria and 5 (2
with possible AD and 3 with probable DLB) withdrew
from the study for personal reasons before undergoing
imaging procedures. These 6 subjects were therefore
excluded from further analyses. Of the remaining 59 sub-
jects, 32 were clinically diagnosed at baseline as having
DLB (probable DLB, n5 27; possible DLB, n5 5) and
27 as having non-DLB dementia (probable AD, n5 8;
possible AD, n5 6; probable bvFTD, n5 9; possible
bvFTD, n5 3; possible bvFTD1 progressive supranuclear
palsy, n5 1). At the 12-month follow-up evaluation, a
change in diagnostic classification (from possible DLB to
probable AD) occurred in 2 subjects; in 7 additional sub-
jects with initial diagnoses of AD (n5 4), DLB (n5 1),
or bvFTD (n5 2), the diagnostic shift was only from the
possible to the probable category. Thus, according to our
final clinical categorization, our two groups were respec-
tively composed of 30 DLB and 29 non-DLB subjects.
Subjects’ demographic and clinical features are
shown in Table 1 (for more clinical details, also see Sup-
plementary Table 1). The DLB and non-DLB groups
were comparable for age at onset, sex, and age and global
severity of dementia at first visit. As expected, compared
to non-DLB, DLB patients showed a considerably greater
frequency of parkinsonism, VHs, and cognitive fluctua-
tions, as well as sleep disturbances and neuropsychiatric
symptoms. Neuropsychologically, compared to non-DLB,
DLB patients were also characterized by lower scores on
tests of visuospatial/constructional and attentional abili-
ties (Table 2).
Sensitivity, specificity, PPV, and NPV for DLB
were respectively 93%, 100%, 100%, and 98% for over-
all visual assessment of myocardial images, and 90%,
76%, 49%, and 97% for striatal images (Supplementary
Tables 2 and 3). Similar rates were obtained with semi-
quantitative assessments (see Supplementary Tables 2 and
3). Of note, whereas sensitivities to DLB between the
two techniques were not statistically different (p5 0.6),
specificity of 123I-MIBG myocardial scintigraphy was sig-
nificantly greater than that of 123I-FP-CIT SPECT for
FIGURE 2: (A) Normal and (B) abnormal 123I-metaiodobenzylguanidine myocardial scintigraphy images. [Color figure can be
viewed in the online issue, which is available at www.annalsofneurology.org.]
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both overall visual rating (p5 0.02) and semiquantitative
results (p5 0.03).
As shown in Table 3 (for more details, also see Sup-
plementary Table 4), 123I-FP-CIT SPECT and 123I-
MIBG myocardial scintigraphy were discordant in 8 of
the 59 (14%) subjects. In the remaining 51 subjects, the
two procedures were concordant, although in 2 subjects
there was a mismatch between the imaging data (both
normal) and the final clinical diagnosis of DLB. More
specifically, within the DLB group (n5 30), 123I-FP-CIT
SPECT and 123I-MIBG myocardial scintigraphy were
concordant in 29 subjects (both abnormal, n5 27; both
normal, n5 2) and discordant (reduction in 123I-MIBG
uptake but not in 123I-FP-CIT uptake) in only 1 subject.
Conversely, within the non-DLB group (n5 29), 123I-
FP-CIT SPECT and 123I-MIBG myocardial scintigraphy
were concordant (both normal) in 22 (76%) subjects and
discordant (reduction in 123I-FP-CIT uptake but not in
123I-MIBG uptake) in 7 (24%) subjects (AD, n5 2; AD
with parkinsonism, n5 1; bvFTD, n5 2; bvFTD with
parkinsonism, n5 2).
Of note, in the non-DLB group, 123I-MIBG myo-
cardial uptake was invariably normal (specificity of
100%), despite the concomitance of diabetes and/or
heart disease in about one-fourth of the patients (see
Supplementary Table 1). Of the 7 non-DLB subjects
with diabetes, 3 had a CIRS comorbidity index 3.
Conversely, of the 4 non-DLB subjects with heart dis-
ease, only 1 had a CIRS comorbidity index 3 (compa-
rable to New York Heart Association [NYHA] class III),
whereas the remaining 3 were only mildly symptomatic
(NYHA classes I or II).
Inter-reader agreement for visual assessment of
myocardial imaging was excellent (Cohen kappa5 0.89
TABLE 1. Sociodemographic and Clinical Data
DLB, n5 30 Non-DLB, n5 29 pa
Age at onset, yr 69.56 5.5 70.86 8.2 0.490
Age at first visit, yr 73.56 4.8 73.36 7.8 0.934
Sex, female 9 (30%) 12 (41%) 0.361
MMSE 21.36 4.0 22.06 4.7 0.523
CDR 0.5/1/2/3 n5 25; 5/11/9/0 n5 24; 5/12/4/3 0.176
IADL, lost functions
Female n5 9, 3.26 3.4 n5 12, 2.46 2.6 0.561
Male n5 21, 2.26 1.4 n5 17, 2.46 1.5 0.719
ADL, lost functions 0.96 1.5 0.356 0.8 0.101
CIRS Severity 1.26 0.2 1.26 0.1 0.497
CIRS Comorbidity 0.86 1.2 0.56 0.7 0.300
UPDRS-III 23.26 16.2 4.76 9.4 <0.0001
Cornell Depression Scale 7.96 6.6 6.86 4.5 0.494
Epworth Sleepiness Scale 7.86 4.8 5.56 3.6 0.048
Mayo Fluctuation Scale 2.16 1.4 0.46 0.7 <0.0001
Clinical Assessment of Fluctuations 5.06 4.1 1.36 2.7 0.0001
NPI 21.96 18.7 14.36 8.9 0.052
North-East Visual Hallucinations Interview, yes 21 (70%) 1 (3%) <0.0001
All values are means6 standard deviation or frequencies. Percentages are in parentheses. For all scales, higher scores denote greater disease severity,
except for the MMSE, for which higher scores represent better cognitive function.
aTwo-tailed unpaired t test, except for sex, CDR, and North-East Visual Hallucinations Interview, for which chi-square test was used.
ADL5Activities of Daily Living Scale; CDR5Clinical Dementia Rating; CIRS5Cumulative Illness Rating Scale; DLB5 dementia with Lewy
bodies; IADL5 Instrumental Activities of Daily Living Scale; MMSE5Mini Mental State Examination; NPI5Neuropsychiatric Inventory;
UPDRS5Unified Parkinson Disease Rating Scale.
Tiraboschi et al: Imaging in DLB
September 2016 373
between the independent readers A and B; 0.93 between
A and C; 0.96 between B and C). Inter-reader agreement
for visual assessment of striatal imaging was also good
(Cohen kappa5 0.82 between readers D and E; 0.86
between D and F; 0.82 between E and F), but not as
high as for myocardial imaging.
Discussion
In the present study, we compared the diagnostic value
of striatal 123I-FP-CIT SPECT and 123I-MIBG myocar-
dial scintigraphy in differentiating DLB from other types
of dementia. Consistent with earlier observations,27 we
noted a greater rate of agreement between the two imag-
ing techniques in DLB (93% with reduced uptake of
both tracers) than non-DLB patients (76% with normal
uptake of both tracers). Of note, in our study, all non-
DLB patients with discrepant imaging results had
reduced uptake of striatal 123I-FP-CIT but normal
uptake of myocardial 123I-MIBG, indicating a full con-
cordance between normality of tracer uptake and a clini-
cal diagnosis of non-DLB exclusively for myocardial
imaging. We also found that the agreement for visual
assessment among our independent readers was consider-
ably greater for myocardial than for striatal imaging.
Altogether, these results suggest that both striatal
123I-FP-CIT SPECT and 123I-MIBG myocardial scintig-
raphy can perform equally well in increasing DLB identi-
fication, but the latter method appears to be more
reliable and accurate for excluding non-DLB dementias,
thereby reducing the risk of overdiagnosis. Is avoiding
TABLE 2. Neuropsychological Data
DLB, n5 30 Non-DLB, n5 29 pa
CERAD–Verbal Fluency 9.46 4.3 9.16 3.5 0.763
CERAD–Boston Naming Test 11.36 3.9 10.96 3.6 0.714
CERAD–Word List Memory 8.46 3.9 10.46 4.2 0.069
CERAD–Constructional Praxis 6.86 2.6 8.96 1.7 0.0004
CERAD–Word List Recall 1.66 1.2 1.56 2.1 0.874
CERAD–Word List Recognition 14.86 4.3 14.56 4.9 0.791
CERAD–Recall of Constructional Praxis 3.26 2.5 2.56 2.9 0.286
CERAD–Copy a Clock 2.16 1.0 1.56 1.2 0.028
Digit Cancellation Test 25.86 12.3 33.36 14.1 0.034
Verbal fluency (Letters) 15.66 7.4 13.66 8.7 0.335
Raw scores are reported. Values are means6 standard deviation. Higher scores denote a better neuropsychological performance, except for
CERAD–Copy a Clock, for which lower scores indicate a better performance.
aTwo-tailed unpaired t test.
CERAD5Consortium to Establish a Registry for Alzheimer’s Disease; DLB5 dementia with Lewy bodies.
TABLE 3. Imaging Findings in Relation to Final Clinical Diagnosis
123I-MIBG Myocardial
Scintigraphy: Overall
Visual Rating
123I-FP-CIT SPECT:
Overall Visual Rating
Abnormal Normal
Abnormal 27 DLB (26 probable; 1 possible) 1 probable DLB
Normal 3 probable bvFTD; 1 possible
bvFTD1PSP; 2 AD (1 probable; 1
possible); 1 probable AD1CVD
13 AD (12 probable; 1 possible);
9 probable bvFTD; 2 DLB
(1 probable; 1 possible)
123I-FP-CIT5 123I-2b-carbomethoxy-3b-(4-iodophenyl)-N-(3-fluoropropyl) nortropane; 123I-MIBG5 123I-metaiodobenzylguanidine;
AD5Alzheimer disease; bvFTD5 behavioral variant frontotemporal dementia; CVD5 cerebrovascular disease; DLB5 dementia with Lewy bod-
ies; PSP5 progressive supranuclear palsy; SPECT5single photon emission computed tomography.
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overdiagnosing DLB a relevant issue in everyday clinical
practice? We feel that it is although, given the high spe-
cificity of probable DLB clinical diagnosis against the
neuropathological diagnosis reported in most of autopsy
controlled studies,6–11 the issue of DLB overdiagnosis has
traditionally received less emphasis in the literature than
that of DLB underdiagnosis. Warning clinicians against
the risk of DLB overdiagnosis, a more recent autopsy
series has, however, questioned the specificity of DLB
Consortium clinical criteria for probable DLB, showing a
comparable distribution of each of the 3 DLB “core
features” between DLB and non-DLB patients.4 A simi-
lar finding was later replicated in another autopsy series,5
where the overlap of DLB core features between DLB
and non-DLB patients appeared to increase with increas-
ing dementia severity. The clinical diagnosis of possible
DLB is even more problematic. The only autopsy study
to report on the accuracy of a possible DLB clinical diag-
nosis noted a specificity of only 28%10—that is, most
had some other pathology accounting for their presenta-
tion—further highlighting the importance of diagnostic
methods capable of increasing DLB diagnostic accuracy
through a proper exclusion of non-DLB dementing
disorders.
To our knowledge, no more than 2 studies27,28
have previously compared the diagnostic value of 123I-
FP-CIT SPECT and 123I-MIBG myocardial scintigraphy
in differentiating DLB from other types of dementia.
However, our experimental design differs from that of
these studies in several respects. To prevent selection bias,
our patients were enrolled consecutively, without exclud-
ing those with concomitant medical conditions potential-
ly interfering with 123I-MIBG uptake; to decrease the
risk of misdiagnosis, all clinical diagnoses were agreed
upon by 2 assessors and reconsidered after 12 months of
follow-up; to guarantee the independence of imaging
evaluation, the nuclear physicians who evaluated the bas-
al ganglia and myocardial images were blinded to the
patients’ clinical information. It is also worth noting that
the group of patients studied was skewed toward the
inclusion of patients with DLB, who accounted for
approximately half of the entire sample. However, this
weighting was justified, because one of our purposes was
to test how the two imaging methods performed in the
positive identification of cases. Also intentional was the
selection of recruiting centers particularly skilled in early
identification of atypical dementias, which explains the
over-representation of FTD patients, generally neglected
in this kind of study. Although rarely, delusion and hallu-
cinations have been reported for FTD patients,20,50 and
their presence may sometimes lead to an erroneous
diagnosis of DLB, in particular when parkinsonism is
also associated.
Several significant points emerge from this study.
First, clinical diagnoses appear to have been accurate
since the first visit. Should we disregard the shift from
the possible to the probable category in 7 patients (1 in
the DLB and 6 in the non-DLB group), which merely
reflects a greater confidence of the clinician in his/her
prior diagnosis, the initial clinical classification has been
confirmed at follow-up visit in all but 2 subjects. Com-
pared to non-DLB patients, those with DLB were
expectedly characterized by an increased frequency of
parkinsonism (and, consequently, by a higher L-dopa
prescription), visual hallucinations, and cognitive fluctua-
tions, and greater visuospatial and executive dysfunction.
Second, despite a comparably high sensitivity for
identifying DLB (93% vs 90%), 123I-MIBG myocardial
scintigraphy appeared to be by far more specific than
123I-FP-CIT SPECT for excluding non-DLB dementias
(100% vs 76%). As a result of these similar sensitivities,
but significantly different specificities, NPV were similar
between the two imaging techniques (98% vs 97%), but
123I-MIBG myocardial scintigraphy had a much greater
PPV than 123I-FP-CIT SPECT (100% vs 49%). Of
note, because DLB cases were over-represented in our
sample (50%), and PPV and NPV depend on the preva-
lence of the disease (see Statistical Analysis), PPV and
NPV were adjusted assuming a DLB prevalence of 20%.
Impressively, each of the 3 independent nuclear physi-
cians rated all of the myocardial images of non-DLB sub-
jects as normal (specificity of 100%). A specificity of
100% for excluding non-DLB dementias was also
reported earlier,17 but our result is even more striking
when considering that, unlike these investigators, in our
“naturalistic” study we also included patients with heart
disease and/or diabetes, whose concomitance may theo-
retically give rise to false-positive results. In our hands,
however, more than one-fourth of the non-DLB subjects
had a history of diabetes and/or heart disease, and yet
their myocardial tracer retention was normal, suggesting
that the potential confounding effects of these medical
conditions on the accuracy of 123I-MIBG scintigraphy
might have been overemphasized.
Third, with specific regard to 123I-FP-CIT SPECT,
we had comparable sensitivity to DLB, but lower specif-
icity than that previously reported in prior studies.14–16
In a recent meta-analysis,18 the overall sensitivity and
specificity of 123I-FP-CIT SPECT to DLB were respec-
tively 86.5% and 93.6%. However, in most of the stud-
ies included in this meta-analysis, the comparison with
DLB patients was largely limited to AD patients with no
or negligible parkinsonism, in whom 123I-FP-CIT uptake
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is usually normal. Conversely, in the present study, the
non-DLB sample included some patients with bvFTD
with variable degrees of parkinsonism, for which the pos-
sibility of abnormal 123I-FP-CIT SPECT images has pre-
viously been recognized.20,21 Had we restricted our
analyses to AD patients (data not shown), specificity fig-
ures (81%) would have been much closer to those previ-
ously reported.18 Therefore, the relatively lower 123I-FP-
CIT SPECT specificity seen in this study than in prior
studies can largely be explained by a greater heterogeneity
of our non-DLB sample.
There are limitations to this study. First, the gold
standard for image validation was a clinical rather than a
neuropathological diagnosis. However, to minimize the
risk of misdiagnosis, all clinical diagnoses were consensu-
ally made by 2 assessors and their appropriateness was
reviewed after 12 months. Another limitation is that data
regarding the possible presence of autonomic dysfunc-
tion, and in particular orthostatic hypotension, were not
systematically recorded. Due to this omission, the possi-
bility that the high rate of abnormal myocardial imaging
(sensitivity of 93%) observed in our DLB group might
have been inflated by an overrepresentation of subjects
with orthostatic hypotension cannot be excluded. Howev-
er, sensitivity values of similar magnitude have also been
reported by many others,48 which is not unexpected,
because reduced myocardial 123I-MIBG uptake in DLB
may also reflect subtle pathologic changes in postgangli-
onic sympathetic cardiac innervation below the threshold
of clinical expression. An apparent limitation may be the
choice of original2 instead of revised12 DLB consensus
criteria. However, the exclusion of 123I-FP-CIT SPECT
from the diagnostic algorithm was required to avoid the
circularity of classifying the DLB subjects using the vari-
able of interest. Moreover, for RBD exclusion, we felt
that information based exclusively on the informant
interview would have exposed us to the risk of overesti-
mating RBD and, consequently, overdiagnosing DLB.
Patients with moderate to severe obstructive sleep apnea
can have features (nightmare and behavior) identical to
RBD.
Finally, although myocardial imaging was rated as
normal in all of our non-DLB patients with heart disease
and/or diabetes, such patients were not sufficiently
numerous in our sample to definitely exclude any inter-
ference of these illnesses on 123I-MIBG uptake.
In summary, in the present study, we compared the
diagnostic value of 123I-FP-CIT SPECT and 123I-MIBG
myocardial scintigraphy in differentiating DLB from oth-
er dementias. We found that the two methods are simi-
larly sensitive to DLB, but 123I-MIBG myocardial
scintigraphy may be more reliable and accurate for
excluding non-DLB dementias, especially when parkin-
sonism is the only core feature exhibited by the patient.
It is particularly in this case that false-positive (abnormal,
low uptake) 123I-FP-CIT SPECT images may be pro-
duced and myocardial 123I-MIBG scintigraphy appears
to be a more appropriate diagnostic option. Overall, our
findings support the view that abnormal (low uptake)
123I-MIBG myocardial scintigraphy should be upgraded
from a “supportive” to a “suggestive” DLB feature. The
observation that 123I-MIBG myocardial uptake was unaf-
fected by concomitant diabetes and/or heart disease sug-
gests that the potential confounding effects of these
medical conditions on 123I-MIBG myocardial scintigra-
phy results might have been overestimated. This needs to
be better elucidated in further studies with larger unse-
lected samples.
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